IPO Guru
Bajaj
Upcoming Opens 27 Nov 2026

Integris Medtech IPO GMP Today – Live Grey Market Premium

No grey market premium has been reported for Integris Medtech IPO yet. Kostak: not available. Subject to Sauda: not available.

Integris Medtech IPO is scheduled to open for subscription on November 27, 2026. The public issue aims to raise around TBA and is offered in a price band of TBA per share, with a market lot of TBA shares. The day-wise GMP trend is below.

Abhishek Vohera, Founder of IPO Guru Researched & reviewed by Abhishek Vohera, Founder, IPO Guru Last updated Figures sourced from the RHP, BSE & NSE

GMP trend

Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 20 Nov, 6:08 PM IST.

Peak GMP
--
No readings yet
Lowest GMP
--
No readings yet
Direction
— stable
Needs two days of GMP
The chart appears once the grey market starts quoting Integris Medtech IPO.

Day-wise GMP

The last reading of each day, newest first. Arrows compare with the previous day.

Date GMP ↑↓ % Kostak Sub. Sauda
No GMP history available yet.

Integris Medtech IPO dates

Key dates from opening to listing. Today is 21 November.

Key dates Opens soon
  1. Open 27 Nov 2026
  2. Close 01 Dec 2026
  3. Allotment 02 Dec 2026
  4. Refund/credit 03 Dec 2026
  5. Listing 04 Dec 2026

Integris Medtech IPO expected listing price

Upper price band plus today's grey market premium.

Issue price (upper band)TBA
Current GMP₹ 0
Listing date04 Dec, 2026
GMP-based listing estimate Not yet available

Disclaimer: The listing price estimate above is based purely on the current grey market premium (GMP) and is not a guaranteed prediction. GMP is an unofficial, unregulated indicator and can change significantly in the 24–48 hours before listing. Do not make investment decisions based solely on GMP.

Is Integris Medtech IPO GMP reliable?

Grey market premium for Integris Medtech IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:

  • 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
  • 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
  • 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
  • 04Cross-check before acting: Review the Integris Medtech IPO full review for a fundamentals-based assessment before making any grey market trades.

Integris Medtech IPO Kostak rate explained

Two ways the grey market trades an IPO application before listing.

Kostak
Not available

The Kostak rate for Integris Medtech IPO is not available. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.

Subject to Sauda
Not available

The Subject to Sauda price is not available. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.

Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.

About Integris Medtech IPO

Integris Medtech Limited was formerly known as Integris Health Private Limited. It describes itself as a diversified India-based global medical products and laboratory solutions company. It develops, makes and sells medical devices and solutions across cardiovascular devices, clinical diagnostics and scientific laboratory solutions. Its products are sold in more than 65 countries as of 30 June 2025.

The company runs three manufacturing facilities in Dehradun, India, and one facility each in Chennai, the Netherlands and Germany. Dehradun houses several of these plants, so output is concentrated in one Indian city. The cardiovascular business depends on nine principal raw material suppliers, and six critical materials come from single suppliers.

Two segments are reported. The lab solutions segment gave Rs 12,412.48 million, or 65.24% of revenue from operations, in FY2025. The cardiovascular segment gave Rs 6,612.18 million, or 34.76%. In the three months ended 30 June 2025 the split was 66.51% and 33.49%.

A large part of sales comes from outside India. Jurisdictions outside India gave 66.12% of revenue from operations in the three months ended 30 June 2025, 64.91% in FY2025, 60.40% in FY2024 and 58.88% in FY2023. The company has also grown through acquisitions, and the document says its business model has relied significantly on them.

The company had 1,879 employees on a consolidated basis as of 30 June 2025, against 1,481 at the end of FY2025. Its promoters are Evercure Holdings Pte. Ltd., Medicore Holdings Pte. Ltd., Gurmit Singh Chugh and Punita Sharma. The registered office is in New Delhi and the corporate office is in Noida.

View full IPO details →

Frequently asked

What is the GMP of Integris Medtech IPO?

The current Grey Market Premium (GMP) of Integris Medtech IPO is not yet started or active in the market.

What is the Kostak Price of Integris Medtech IPO?

Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Integris Medtech IPO is not available.

What is the Subject to Sauda Price of Integris Medtech IPO?

Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.

What is the expected listing price of Integris Medtech IPO based on GMP?

The listing price estimate is not yet available as GMP has not been established for Integris Medtech IPO. Check back closer to the subscription date.

Is the GMP of Integris Medtech IPO increasing or decreasing?

The GMP of Integris Medtech IPO is currently stable. Track the day-wise GMP table above for the latest movement.

Explore Integris Medtech IPO further

The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.

Opens 27 November 2026

GMP is a mood, not a forecast.

IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.

Join the WhatsApp channel All live IPO GMP

Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.

GMP
₹ 0
Kostak
—
Est. listing
TBA
Full IPO details
Advertisement